DFX Intelligence

Data Factory

Private equityFirmbuyoutmiddle market

Novaquest Capital Management, L.L.C.

Private Equity

Raleigh, NC

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:c6bb9878-1785-4bdc-9bad-481c9dc64873

Data as of Sep 15, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 5:30 AM UTC and rebuilt at most every 15 minutes.

Relationships: 134
Dated events: 40
On other graphs: 1
Observed: Sep 13, 2026 to Sep 15, 2026
32 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

RIA / Wealth Managementidentity

NOVAQUEST CAPITAL MANAGEMENT, L.L.C.

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 45
PE funds: 45
Vintages: 2014 to 2024
PE GAV, 2024 filing: $3.3Bgross asset value on Form ADV; never dry powder
Regulatory AUM: $1.8B
Investments: 30
Active investments: 0
Size band: MIDDLE MARKETderivedproxy: $3.25bn Private Equity Fund GAV on the Form ADV filed 2024-10-11
Stated sectors: healthcare,technology
Latest ADV filing: Oct 11, 2024
Employees (ADV): 26
Website: novaquest.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
Novaquest Pharma Opportunities Fund VI, L.P.	2024	Unknown	Private Equity Fund	n/a	$88.1M
NQ Project Lockport, L.P.	2024	Unknown	Private Equity Fund	n/a	$11.8M
Novaquest Co-Investment Fund Xvii, L.P.	2023	Early deployment	Private Equity Fund	n/a	$50.6M
NQ Project Phoebus, L.P.	2023	Early deployment	Private Equity Fund	n/a	$53.2M
NQ Project Bridgeton, L.P.	2023	Early deployment	Private Equity Fund	n/a	$85.6M
NQ Project Sampson, L.P.	2023	Early deployment	Private Equity Fund	n/a	$40.9M
NQ Project Glasgow, Ltd.	2023	Early deployment	Private Equity Fund	n/a	$83.9M
NQ Ah Project Arlington II, L.P.	2023	Early deployment	Private Equity Fund	n/a	$18.6M
NQ Project Pharaoh, L.P.	2023	Early deployment	Private Equity Fund	n/a	$130M
NQ Cove Aggregator, L.P.	2022	Early deployment	Private Equity Fund	n/a	$46.6M
Novaquest Animal Health Opportunities Fund, L.P.	2022	Early deployment	Private Equity Fund	n/a	$8.6M
Novaquest Co-Investment Fund Xvi, L.P.	2022	Unknown	Private Equity Fund	n/a	$72.8M
Novaquest Animal Health Opportunities Fund (delaware), L.P.	2022	Early deployment	Private Equity Fund	n/a	$117M
Novaquest Animal Health Opportunities Fund Aggregator, L.P.	2022	Early deployment	Private Equity Fund	n/a	$132M
Novaquest Co-Investment Fund Xv, L.P.	2022	Unknown	Private Equity Fund	n/a	$15.1M
Novaquest Co-Investment Fund Xviii, L.P.	2022	Early deployment	Private Equity Fund	n/a	$54.1M
Novaquest Co-Investment Fund I (parent), L.P.	2021	Active deployment	Private Equity Fund	n/a	$709,000
Novaquest Co-Investment Fund Xiv, L.P.	2021	Wound down	Private Equity Fund	n/a	$30.8M
Novaquest Co-Investment Fund Xiii, L.P.	2021	Unknown	Private Equity Fund	n/a	$24.2M
Novaquest Co-Investment Fund Ix, L.P.	2020	Active deployment	Private Equity Fund	n/a	$66.7M
Novaquest Co-Investment Fund Xi, L.P.	2020	Active deployment	Private Equity Fund	n/a	$30.5M
NQP Spv II, L.P.	2020	Mature	Private Equity Fund	n/a	$95.0M
Novaquest Co-Investment Fund X, L.P.	2020	Active deployment	Private Equity Fund	n/a	$4.9M
Novaquest Fund III Aiv I, L.P.	2019	Wound down	Private Equity Fund	n/a	$357,000
Novaquest Co-Investment - Risp, L.P.	2019	Harvest	Private Equity Fund	n/a	$17.8M

Investments

Company	State	Role	Control	Invested	Exited	Status
Hansa Biopharma	n/a	unknown	unknown	n/a	n/a	unknown
Hospira	n/a	unknown	unknown	n/a	n/a	unknown
Lupin	n/a	unknown	unknown	n/a	n/a	unknown
Mesoblast	n/a	unknown	unknown	n/a	n/a	unknown
Mileutis	n/a	unknown	unknown	n/a	n/a	unknown
MI RNA	n/a	unknown	unknown	n/a	n/a	unknown
Mundi Pharma	n/a	unknown	unknown	n/a	n/a	unknown
Mycovia Pharmaceuticals	n/a	unknown	unknown	n/a	n/a	unknown
Myovant	n/a	unknown	unknown	n/a	n/a	unknown
Nevakar	n/a	unknown	unknown	n/a	n/a	unknown
Pfizer	n/a	unknown	unknown	n/a	n/a	unknown
Phathom Pharmaceuticals	n/a	unknown	unknown	n/a	n/a	unknown
Precision	n/a	unknown	unknown	n/a	n/a	unknown
Revance	n/a	unknown	unknown	n/a	n/a	unknown
Roivant	n/a	unknown	unknown	n/a	n/a	unknown
Sebela Pharmaceuticals Inc.	n/a	unknown	unknown	n/a	n/a	unknown
Sanofi	n/a	unknown	unknown	n/a	n/a	unknown
Shionogi	n/a	unknown	unknown	n/a	n/a	unknown
Takeda	n/a	unknown	unknown	n/a	n/a	unknown
Targan	n/a	unknown	unknown	n/a	n/a	unknown
Gallant	n/a	unknown	unknown	n/a	n/a	unknown
Aceragen	n/a	unknown	unknown	n/a	n/a	unknown
Argenta	n/a	unknown	unknown	n/a	n/a	unknown
Arvelle Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
California Cryobank	n/a	unknown	unknown	n/a	n/a	unknown
Cerevel	n/a	unknown	unknown	n/a	n/a	unknown
Covenant	n/a	unknown	unknown	n/a	n/a	unknown
Dermavant	n/a	unknown	unknown	n/a	n/a	unknown
FibroGen	n/a	unknown	unknown	n/a	n/a	unknown
Grunenthal	n/a	unknown	unknown	n/a	n/a	unknown

Relationships

showing 80 of 134

Employs (17)

→ Ryan WootenPersonManaging Director
factThe subject's own site
→ Trisha TolerPersonAccounting Manager
factThe subject's own site
→ Dean MoorePersonController
factThe subject's own site
→ Bryan Edwards MillsPersonMember, Chief Administrative Officer, Management Committee Member
Jan 1, 2020 to presentfactForm ADV, The subject's own site
→ Chris MauneyPersonVice President
factThe subject's own site
→ Erin McStravickPersonHead of Investor Relations
factThe subject's own site
→ Patrick Brooks JordanPersonMember, Managing Partner, Chief Operating Officer, Management Committee Member
Apr 1, 2021 to presentfactForm ADV, The subject's own site
→ Halsey HutchinsonPersonSenior Associate
factThe subject's own site
→ Devin Weiss HoldenPersonChief Compliance Officer
Jan 1, 2024 to presentfactForm ADV, The subject's own site
→ Brian AxePersonPartner
factThe subject's own site
→ Michael James BolognaPersonMember, Chief Investment Officer, Management Committee Member
Jul 1, 2023 to presentfactForm ADV, The subject's own site
→ Angela ColeyPersonBioPharma Relations Manager
factThe subject's own site
→ Robert Wayne HesterPersonMember, Chief Financial Officer, Executive Vice President
Nov 1, 2010 to presentfactForm ADV, The subject's own site
→ Dennis B. GillingsPersonShareholder
Jan 1, 2022 to presentfactForm ADV
→ Yoshitaka OshibaPersonManagement Committee Member
Aug 1, 2024 to presentfactForm ADV
→ Mireille GillingsPersonShareholder
Jan 1, 2022 to presentfactForm ADV
→ Ernest Gerald BrownPersonManagement Committee Member
Nov 1, 2010 to presentfactForm ADV

Invested in (30)

→ Mycovia PharmaceuticalsCompanyunknown
factThe subject's own site
→ Mundi PharmaCompanyunknown
factThe subject's own site
→ MI RNACompanyunknown
factThe subject's own site
→ MileutisCompanyunknown
factThe subject's own site
→ MesoblastCompanyunknown
factThe subject's own site
→ LupinCompanyunknown
factThe subject's own site
→ HospiraCompanyunknown
factThe subject's own site
→ Hansa BiopharmaCompanyunknown
factThe subject's own site
→ GrunenthalCompanyunknown
factThe subject's own site
→ GallantCompanyunknown
factThe subject's own site
→ FibroGenCompanyunknown
factThe subject's own site
→ MyovantCompanyunknown
factThe subject's own site
→ TarganCompanyunknown
factThe subject's own site
→ TakedaCompanyunknown
factThe subject's own site
→ ShionogiCompanyunknown
factThe subject's own site
→ SANOFICompanyunknown
factThe subject's own site
→ Sebela Pharmaceuticals Inc.Companyunknown
factThe subject's own site
→ RoivantCompanyunknown
factThe subject's own site
→ RevanceCompanyunknown
factThe subject's own site
→ PrecisionCompanyunknown
factThe subject's own site
→ Phathom PharmaceuticalsCompanyunknown
factThe subject's own site
→ PfizerCompanyunknown
factThe subject's own site
→ NevakarCompanyunknown
factThe subject's own site
→ DermavantCompanyunknown
factThe subject's own site
→ AceragenCompanyunknown
factThe subject's own site
→ ArgentaCompanyunknown
factThe subject's own site
→ Arvelle TherapeuticsCompanyunknown
factThe subject's own site
→ California CryobankCompanyunknown
factThe subject's own site
→ CerevelCompanyunknown
factThe subject's own site
→ CovenantCompanyunknown
factThe subject's own site

Firm member (1)

→ Novaquest CapitalFirmAnchor adviser
factDFX's own graph

Manages (27)

→ Novaquest Pharma Opportunities Fund VI, L.P.FundPrivate Equity Fund
Mar 29, 2024 to presentfactForm ADV
→ NQP Spv II, L.P.FundPrivate Equity Fund
Mar 30, 2020 to presentfactForm ADV
→ Novaquest Co-Investment Fund Ix, L.P.FundPrivate Equity Fund
Mar 30, 2020 to presentfactForm ADV
→ NQ PE Project Aware, L.P.FundPrivate Equity Fund
Mar 30, 2020 to presentfactForm ADV
→ Novaquest Co-Investment Fund I (parent), L.P.FundPrivate Equity Fund
Mar 30, 2021 to presentfactForm ADV
→ NQ PE Project Inca Rollover, L.P.FundPrivate Equity Fund
Mar 30, 2021 to presentfactForm ADV
→ Novaquest Co-Investment Fund Xiii, L.P.FundPrivate Equity Fund
Mar 30, 2021 to presentfactForm ADV
→ Novaquest Co-Investment Fund Xiv, L.P.FundPrivate Equity Fund
Mar 30, 2021 to presentfactForm ADV
→ NQ PE Project Sigma, L.P.FundPrivate Equity Fund
Mar 30, 2021 to presentfactForm ADV
→ NQ PE Project Stingray Co-Invest, L.P.FundPrivate Equity Fund
Mar 30, 2021 to presentfactForm ADV
→ Novaquest Animal Health Opportunities Fund Aggregator, L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ Novaquest Co-Investment Fund Xvi, L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ NQ Cove Aggregator, L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ Novaquest Co-Investment Fund Xv, L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ Novaquest Co-Investment Fund Xviii, L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ Novaquest Animal Health Opportunities Fund, L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ Novaquest Animal Health Opportunities Fund (delaware), L.P.FundPrivate Equity Fund
Mar 31, 2022 to presentfactForm ADV
→ NQ Ah Project Arlington II, L.P.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ NQ Project Sampson, L.P.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ Novaquest Co-Investment Fund Xvii, L.P.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ NQ Project Pharaoh, L.P.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ NQ Project Glasgow, Ltd.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ NQ Project Phoebus, L.P.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ NQ Project Bridgeton, L.P.FundPrivate Equity Fund
Mar 31, 2023 to presentfactForm ADV
→ NQ Project Lockport, L.P.FundPrivate Equity Fund
Mar 29, 2024 to presentfactForm ADV
→ Novaquest Pharma Opportunities Fund III, L.P.FundPrivate Equity Fund
Feb 14, 2012 to presentfactForm ADV
→ Novaquest Co-Investment Fund I, L.P.FundPrivate Equity Fund
Mar 27, 2014 to presentfactForm ADV

Dated events

25 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Dec 10, 2025
Firm news
Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market
The subject's own siteobserved 4 days ago
Occurred
Jun 30, 2025
Firm news
Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market 6.30.25
The subject's own siteobserved 4 days ago
Occurred
Sep 3, 2024
Person left
Hidekazu Tanaka (Management Committee Member) no longer on Schedule A of Novaquest Capital Management, L.L.C.
Form ADVobserved 6 days ago
Occurred
Sep 3, 2024
Person left
Jonathan Edward Tunnicliffe (Member, Founding Partner) no longer on Schedule A of Novaquest Capital Management, L.L.C.
Form ADVobserved 6 days ago
Occurred
Aug 1, 2024
Firm news
AbbVie Completes Acquisition of Cerevel Therapeutics 8.1.24
The subject's own siteobserved 4 days ago
Occurred
Aug 1, 2024
Person joined
Yoshitaka Oshiba joined Schedule A of Novaquest Capital Management, L.L.C. as Management Committee Member
Form ADVobserved 6 days ago
Occurred
Mar 29, 2024
Person left
Ronald John Wooten (Member, Senior Founding Partner, Management Committee Member) no longer on Schedule A of Novaquest Capital Management, L.L.C.
Form ADVobserved 6 days ago
Occurred
Feb 29, 2024
Person left
Jacob Ernest Comer (Member, General Counsel & Chief Compliance Officer) no longer on Schedule A of Novaquest Capital Management, L.L.C.
Form ADVobserved 6 days ago
Occurred
Jan 1, 2024
Person joined
Devin Weiss Holden joined Schedule A of Novaquest Capital Management, L.L.C. as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Nov 20, 2023
Person left
John Layton Bradley (Member, Founding Partner, Management Committee Member) no longer on Schedule A of Novaquest Capital Management, L.L.C.
Form ADVobserved 6 days ago
Occurred
Jul 1, 2023
Person joined
Michael James Bologna joined Schedule A of Novaquest Capital Management, L.L.C. as Member, Chief Investment Officer
Form ADVobserved 6 days ago
Occurred
Jan 1, 2022
Person joined
Mireille Gillings joined Schedule A of Novaquest Capital Management, L.L.C. as Shareholder
Form ADVobserved 6 days ago
Occurred
Jun 30, 2021
Person left
Ryohei Umezawa (Management Committee Member) no longer on Schedule A of Novaquest Capital Management, L.L.C.
Form ADVobserved 6 days ago
Occurred
Apr 1, 2021
Person joined
Hidekazu Tanaka joined Schedule A of Novaquest Capital Management, L.L.C. as Management Committee Member
Form ADVobserved 6 days ago
Occurred
Apr 1, 2021
Person joined
Patrick Brooks Jordan joined Schedule A of Novaquest Capital Management, L.L.C. as Member, Managing Partner, Chief Operating Officer
Form ADVobserved 6 days ago

Show 25 bookkeeping events

Occurred
Mar 31, 2026
Novaquest Capital Management, L.L.C.: Private Equity Funds on Form ADV 39 (2024 extract) -> 13 (roster 2026-09-01)
Occurred
Mar 29, 2024
Fund 805-2854660871 no longer reported on Form ADV by Novaquest Capital Management, L.L.C.
Occurred
Mar 29, 2024
Fund 805-8104228532 no longer reported on Form ADV by Novaquest Capital Management, L.L.C.
Occurred
Mar 29, 2024
Novaquest Pharma Opportunities Fund VI, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $88,071,000
Occurred
Mar 29, 2024
NQ Project Lockport, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $11,788,000
Occurred
Mar 31, 2023
NQ Project Bridgeton, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $73,345,000
Occurred
Mar 31, 2023
NQ Project Glasgow, Ltd. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $75,582,000
Occurred
Mar 31, 2023
NQ Project Pharaoh, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $129,408,000
Occurred
Mar 31, 2023
Fund 805-5447243072 no longer reported on Form ADV by Novaquest Capital Management, L.L.C.
Occurred
Mar 31, 2023
NQ Project Sampson, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $35,517,000
Occurred
Mar 31, 2023
NQ Ah Project Arlington II, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $13,400,000
Occurred
Mar 31, 2023
Novaquest Co-Investment Fund Xvii, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $50,177,000
Occurred
Mar 31, 2023
NQ Project Phoebus, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $51,063,000
Occurred
Mar 31, 2023
Fund 805-8119102812 no longer reported on Form ADV by Novaquest Capital Management, L.L.C.
Occurred
Mar 31, 2022
NQ Cove Aggregator, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $12,867,000
Occurred
Mar 31, 2022
Novaquest Co-Investment Fund Xv, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $35,001,000
Occurred
Mar 31, 2022
Novaquest Animal Health Opportunities Fund Aggregator, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $83,885,000
Occurred
Mar 31, 2022
Novaquest Co-Investment Fund Xvi, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $62,500,000
Occurred
Mar 31, 2022
Novaquest Animal Health Opportunities Fund (delaware), L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $77,698,000
Occurred
Mar 31, 2022
Novaquest Co-Investment Fund Xviii, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $30,004,000
Occurred
Mar 31, 2022
Novaquest Animal Health Opportunities Fund, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $5,752,000
Occurred
Mar 30, 2021
Novaquest Co-Investment Fund Xiv, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $29,995,000
Occurred
Mar 30, 2021
NQ PE Project Sigma, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $10,451,000
Occurred
Mar 30, 2021
Novaquest Co-Investment Fund Xiii, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $20,149,000
Occurred
Mar 30, 2021
NQ PE Project Stingray Co-Invest, L.P. first reported on Form ADV by Novaquest Capital Management, L.L.C. (Private Equity Fund), GAV $43,125,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Ryan Wooten
Managing Director · Revealable: 1 professional profile (firm website)
Trisha Toler
Accounting Manager · Revealable: 1 professional profile (firm website)
Dean Moore
Controller · Revealable: 1 professional profile (firm website)
Bryan Edwards Mills
Member, Chief Administrative Officer, Management Committee Member · Revealable: 1 professional profile (firm website)
Chris Mauney
Vice President · Revealable: 1 professional profile (firm website)
Erin McStravick
Head of Investor Relations · Revealable: 1 professional profile (firm website)
Patrick Brooks Jordan
Member, Managing Partner, Chief Operating Officer, Management Committee Member · Revealable: 1 professional profile (firm website)
Halsey Hutchinson
Senior Associate · Revealable: 1 professional profile (firm website)
Devin Weiss Holden
Chief Compliance Officer · Revealable: 1 professional profile (firm website)
Brian Axe
Partner · Revealable: 1 professional profile (firm website)
Michael James Bologna
Member, Chief Investment Officer, Management Committee Member · Revealable: 1 professional profile (firm website)
Angela Coley
BioPharma Relations Manager · Revealable: 1 professional profile (firm website)
Robert Wayne Hester
Member, Chief Financial Officer, Executive Vice President · Revealable: 1 professional profile (firm website)

Also named here, with no published line of their own (reach them through the firm): Dennis B. Gillings (Shareholder), Yoshitaka Oshiba (Management Committee Member), Mireille Gillings (Shareholder), Ernest Gerald Brown (Management Committee Member).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan